Pasireotide side 5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-N-methylbenzamide

5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-N-methylbenzamide

MR (3000 nM)

is a phosphodiesterase inhibitor selective for the PDE10A subtype

and induce differentiation of human ESCs/iPSCs toward neural or mesendoderm lineages under appropriate conditions

Benzylpenicillin potassium

Pasireotide side 5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-N-methylbenzamidePasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40 fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Product information CAS Number: 396091 73 9 Molecular Weight: 1047. 21 Formula: C58H66N10O9 Synonym: SOM 230 Signifor SOM 320